JP2018515612A - 置換キノキサリン誘導体 - Google Patents

置換キノキサリン誘導体 Download PDF

Info

Publication number
JP2018515612A
JP2018515612A JP2018511333A JP2018511333A JP2018515612A JP 2018515612 A JP2018515612 A JP 2018515612A JP 2018511333 A JP2018511333 A JP 2018511333A JP 2018511333 A JP2018511333 A JP 2018511333A JP 2018515612 A JP2018515612 A JP 2018515612A
Authority
JP
Japan
Prior art keywords
methyl
quinoxalin
indol
amine
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018511333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515612A5 (https=
Inventor
ロベール イーブ ファブリシウス シャルル−アンリ
ロベール イーブ ファブリシウス シャルル−アンリ
オクタビアン ノバク マテウシュ
オクタビアン ノバク マテウシュ
アンナ ビクリク カタジーナ
アンナ ビクリク カタジーナ
バルバラ サビニャジュ アレクサンドラ
バルバラ サビニャジュ アレクサンドラ
ドミニク ビエン マルチン
ドミニク ビエン マルチン
マウゴジャタ ブダ アンナ
マウゴジャタ ブダ アンナ
シュチェパン グジク パベウ
シュチェパン グジク パベウ
ロマン ヤクビエク クシシュトフ
ロマン ヤクビエク クシシュトフ
マチュシェク モニカ
マチュシェク モニカ
クフィエチンスカ カタジーナ
クフィエチンスカ カタジーナ
ミハウ トムチク マテウシュ
ミハウ トムチク マテウシュ
ミコワイ ガウェンズフスキ ミハウ
ミコワイ ガウェンズフスキ ミハウ
ゴンデラ アンジェイ
ゴンデラ アンジェイ
ピョトル ドゥデク ウーカシュ
ピョトル ドゥデク ウーカシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ryvu Therapeutics SA
Original Assignee
Ryvu Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryvu Therapeutics SA filed Critical Ryvu Therapeutics SA
Publication of JP2018515612A publication Critical patent/JP2018515612A/ja
Publication of JP2018515612A5 publication Critical patent/JP2018515612A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018511333A 2015-05-13 2016-05-12 置換キノキサリン誘導体 Pending JP2018515612A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15460017.5 2015-05-13
EP15001451.2 2015-05-13
EP15001451 2015-05-13
EP15460017 2015-05-14
PCT/EP2016/000783 WO2016180536A1 (en) 2015-05-13 2016-05-12 Substituted quinoxaline derivatives

Publications (2)

Publication Number Publication Date
JP2018515612A true JP2018515612A (ja) 2018-06-14
JP2018515612A5 JP2018515612A5 (https=) 2019-06-13

Family

ID=56081443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511333A Pending JP2018515612A (ja) 2015-05-13 2016-05-12 置換キノキサリン誘導体

Country Status (9)

Country Link
US (1) US20180148429A1 (https=)
EP (1) EP3294729A1 (https=)
JP (1) JP2018515612A (https=)
CN (1) CN107635986A (https=)
AU (1) AU2016261031A1 (https=)
CA (1) CA2979302A1 (https=)
IL (1) IL254870A0 (https=)
TW (1) TW201713641A (https=)
WO (1) WO2016180536A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528247A (ja) * 2016-07-14 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 二環式ヘテロアリール置換化合物
JP2024522354A (ja) * 2021-06-02 2024-06-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Ｒｎａを標的とするリガンド、それらの組成物、及びそれらを作製し使用する方法
WO2025084787A1 (ko) * 2023-10-17 2025-04-24 가천대학교 산학협력단 신규 퀴녹살린 화합물, 이의 제조방법 및 이의 용도

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109890809A (zh) * 2016-11-08 2019-06-14 默克专利股份公司 作为pfkfb的抑制剂的取代的喹喔啉衍生物
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
EP3689866A4 (en) * 2017-09-26 2021-07-07 Nippon Soda Co., Ltd. QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
PE20201185A1 (es) 2018-03-22 2020-11-03 Hoffmann La Roche Inhibidores de la oxacina monoacilglicerol lipasa (magl)
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
ES2986417T3 (es) 2018-08-13 2024-11-11 Hoffmann La Roche Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
AU2019362747A1 (en) * 2018-10-15 2021-06-03 Gero Pte. Ltd. PFKFB3 inhibitors and their uses
ES2955037T3 (es) 2018-11-22 2023-11-28 Hoffmann La Roche Nuevos compuestos heterocíclicos
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
MX2022001548A (es) * 2019-08-06 2022-04-18 Univ North Carolina Chapel Hill Ligandos que se dirigen a arn, composiciones de estos y métodos para elaborarlos y utilizarlos.
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
PE20221450A1 (es) 2019-09-23 2022-09-21 Hoffmann La Roche Compuestos heterociclicos
EP4146652A1 (en) * 2020-05-08 2023-03-15 Merck Patent GmbH Tricyclic heterocycles useful as tead binders
PH12022553233A1 (en) * 2020-07-23 2024-02-12 Cancer Research Tech Ltd Tricyclic heterocycles
WO2022043284A1 (en) 2020-08-26 2022-03-03 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as magl inhibitors
MX2023002224A (es) 2020-09-03 2023-03-15 Hoffmann La Roche Compuestos heterociclicos.
TW202237610A (zh) 2020-11-25 2022-10-01 法商施維雅藥廠 新穎有機化合物
JP2025525350A (ja) 2022-06-24 2025-08-05 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ阻害剤としての新規複素環－カルボニル－環式化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103557A1 (en) * 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
JP2013028588A (ja) * 2011-06-24 2013-02-07 Ishihara Sangyo Kaisha Ltd 有害生物防除剤
JP2015512398A (ja) * 2012-03-29 2015-04-27 アドヴァンスト キャンサー セラピューティクス エルエルシーＡｄｖａｎｃｅｄ Ｃａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ Ｐｆｋｆｂ２阻害剤および抗癌治療法としての使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US20140128392A1 (en) * 2009-03-19 2014-05-08 Bioenergenix Heterocyclic compounds for the inhibition of pask

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103557A1 (en) * 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
JP2013028588A (ja) * 2011-06-24 2013-02-07 Ishihara Sangyo Kaisha Ltd 有害生物防除剤
JP2015512398A (ja) * 2012-03-29 2015-04-27 アドヴァンスト キャンサー セラピューティクス エルエルシーＡｄｖａｎｃｅｄ Ｃａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ Ｐｆｋｆｂ２阻害剤および抗癌治療法としての使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 22, JPN6020001673, 2014, pages 1029 - 1039, ISSN: 0004196256 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528247A (ja) * 2016-07-14 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 二環式ヘテロアリール置換化合物
JP7058256B2 (ja) 2016-07-14 2022-04-21 ブリストル－マイヤーズ スクイブ カンパニー 二環式ヘテロアリール置換化合物
JP2024522354A (ja) * 2021-06-02 2024-06-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Ｒｎａを標的とするリガンド、それらの組成物、及びそれらを作製し使用する方法
WO2025084787A1 (ko) * 2023-10-17 2025-04-24 가천대학교 산학협력단 신규 퀴녹살린 화합물, 이의 제조방법 및 이의 용도

Also Published As

Publication number Publication date
AU2016261031A1 (en) 2017-10-05
TW201713641A (zh) 2017-04-16
EP3294729A1 (en) 2018-03-21
CA2979302A1 (en) 2016-11-17
WO2016180536A1 (en) 2016-11-17
IL254870A0 (en) 2017-12-31
CN107635986A (zh) 2018-01-26
US20180148429A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
JP2018515612A (ja) 置換キノキサリン誘導体
JP6586104B2 (ja) ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法
CN106170486B (zh) 新吲唑甲酰胺、其制备方法、包含其的药物制剂及其用于制备药物的用途
WO2020239077A1 (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN103998042B (zh) Pi3k的活性或功能的抑制剂的应用
KR20210111252A (ko) Irak 분해제 및 이의 용도
CN107474050B (zh) 6，7-二氢吡唑并[1，5-a]吡嗪-4(5H)-酮化合物
EP4667458A1 (en) Pharmaceutical composition for treatment of cancer, comprising sos1 inhibitor and anticancer drug
JP2019081786A (ja) Ｔｒｋａキナーゼ阻害剤としてのｎ−ピロリジニル、ｎ’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物
CN110036004A (zh) 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
EP3560924A1 (de) Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
CN101321756A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物
CN113423707A (zh) Erk抑制剂及其用途
CN101772500A (zh) 作为蛋白质激酶抑制剂的咪唑并吡嗪
CN102675282B (zh) 取代的喹啉化合物及其使用方法和用途
CN105452257A (zh) 新型稠合嘧啶化合物或其盐
JP2021504380A (ja) Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
CN114907338B (zh) 含氮多环稠环类化合物，其药物组合物、制备方法和用途
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
JP2021516674A (ja) ５−ヘテロアリール置換イミダゾール−３−カルボキサミドならびにその調製および使用の方法
TW201710250A (zh) 經取代之喹喏啉衍生物
WO2021233236A1 (zh) 取代的杂芳基化合物及其组合物和用途
IL325136A (en) Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a
HK40100302A (zh) 作为激酶抑制剂的吲唑类化合物
HK40012363A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200901